Production (Stage)
Oramed Pharmaceuticals Inc.
ORMP
$2.22
$0.073.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 196.74% | -- | -100.00% | -100.00% | -75.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 196.74% | -- | -100.00% | -100.00% | -75.06% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -98.07% | -- | -100.00% | -100.00% | -75.06% |
| SG&A Expenses | -17.62% | -20.66% | -29.84% | -30.08% | -23.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.95% | -25.30% | -44.77% | -56.58% | -61.89% |
| Operating Income | -5.89% | 18.95% | 39.61% | 52.22% | 60.86% |
| Income Before Tax | -339.54% | -412.89% | 142.25% | 207.55% | 133.48% |
| Income Tax Expenses | -- | -- | -- | 1,534.00% | -- |
| Earnings from Continuing Operations | -376.35% | -475.45% | 125.92% | 199.22% | 133.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -81.61% | -90.16% | -87.63% | -84.47% | -80.37% |
| Net Income | -370.07% | -444.98% | 127.30% | 203.32% | 135.41% |
| EBIT | -5.89% | 18.95% | 39.61% | 52.22% | 60.86% |
| EBITDA | -6.34% | 19.17% | 40.16% | 52.81% | 61.39% |
| EPS Basic | -368.44% | -446.70% | 127.23% | 200.02% | 134.14% |
| Normalized Basic EPS | -42.16% | -11.68% | 21.11% | 112.66% | 68.21% |
| EPS Diluted | -382.35% | -472.91% | 124.82% | 197.69% | 133.42% |
| Normalized Diluted EPS | -45.61% | -13.73% | 20.79% | 112.40% | 68.58% |
| Average Basic Shares Outstanding | 1.06% | 1.32% | 1.92% | 2.50% | 2.97% |
| Average Diluted Shares Outstanding | 0.38% | 1.53% | 3.40% | 3.99% | 4.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |